Brief: Galectin Therapeutics Inc - Belapectin Well Tolerated With No Safety Signals
20/12/2024 14:19
Dec 20 (Reuters) - Galectin Therapeutics Inc GALT.O :
* BELAPECTIN WELL TOLERATED WITH NO SAFETY SIGNALS
* BELAPECTIN DID NOT ACHIEVE STATISTICAL SIGNIFICANCE IN
INTENT-TO-TREAT POPULATION
* BELAPECTIN SHOWS SIGNIFICANT REDUCTION IN ESOPHAGEAL
VARICES IN
2MG/KG COHORT
Source text: ID:n0001140361-24-050005
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study